SAN JOSE, Calif., June 22, 2016 Integrated Device Technology, Inc. (IDT) (NASDAQ: IDTI) announced today that an implantable long-term glucose sensor using IDT's sensing technology has received government approval to be marketed in European Union (EU) member countries. Maryland-based Senseonics received the CE Mark approval for its Eversense® Continuous Glucose Monitoring (CGM) System, featuring an implanted glucose sensor that lasts up to 90 days, or about six times longer than non-implantable systems currently on the market.
The IDT® sensing solution incorporates an LED driver, temperature sensor, photodiodes and other components in a compact package to drive glucose measurements, which are wirelessly communicated to an on-body wearable transmitter.
"Anyone treating diabetes knows all too well the importance of keeping close watch of glucose levels," said Dr. Andrew Dehennis, director of engineering at Senseonics. "IDT provides a unique semiconductor-based technology with extremely low power consumption, enabling the Eversense system to help the millions of people with diabetes looking for a long-lasting, accurate, easy-to-use continuous glucose monitoring system."
In developing the semiconductor for Senseonics, IDT engineers selected a technology usually used for hearing aids that can be operated at a voltage as low as 0.85 V.
"Senseonics' use of our novel technology to develop its Eversense CGM system is a great example of how miniaturized advanced electronics are contributing to improvements in medical care," said Uwe Guenther, director of mobile sensing at IDT. "The IDT technology used provides an unparalleled level of system integration to deliver the requisite quality and reliability—all in one implantable single-chip solution."
The biotech company Roche announced last month that it will market the Eversense CGM System in Italy, Germany and the Netherlands.
Integrated Device Technology, Inc. develops system-level solutions that optimize its customers' applications. IDT's market-leading products in RF, timing, wireless power transfer, serial switching, interfaces and sensing solutions are among the company's broad array of complete mixed-signal solutions for the communications, computing, consumer, automotive and industrial segments. Headquartered in San Jose, Calif., IDT has design, manufacturing, sales facilities and distribution partners throughout the world. IDT stock is traded on the NASDAQ Global Select Stock Market® under the symbol "IDTI." Additional information about IDT is accessible at www.IDT.com. Follow IDT on Facebook, LinkedIn, Twitter, YouTube and Google+.
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics' first generation continuous glucose monitoring system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.
2016, IDT. IDT and the IDT logo are trademarks or registered trademarks of Integrated Device Technology, Inc. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.
IDT Press Contact:
Public Relations Manager
Phone: (408) 284-2608
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/implantable-glucose-sensor-featuring-idt-sensing-technology-awarded-ce-mark-300288298.html
SOURCE Integrated Device Technology, Inc.